© 2020 MJH Life Sciences and Urology Times. All rights reserved.
Kidney Cancer
FDA grants novel HIF-2α inhibitor accelerated regulatory pathway in renal cell carcinoma
July 29, 2020
The novel HIF-2α inhibitor MK-6482 led to a decrease in the size of target lesions in almost 90% of patients with von Hippel-Lindau disease–associated renal cell carcinoma.
Nephrectomy after immunotherapy can achieve complete response in selected patients
July 27, 2020
A study author said that “the long exposure [to immune checkpoint inhibitor therapy] results in challenging surgery.”
How do you decide between partial and radical nephrectomy?
July 24, 2020
“It’s case dependent. For appropriately selected patients, partial nephrectomy is preferred," says one urologist.
Cabozantinib/atezolizumab phase 3 combo trial launched in renal cell carcinoma
July 20, 2020
The phase 3 CONTACT-03 trial is exploring the combination of the multikinase inhibitor and immunotherapy agent in patients with renal cell carcinoma after exposure to an immune-checkpoint inhibitor.
No survival falloff with use of minimally invasive surgery in early-stage kidney cancer
July 13, 2020
Minimally invasive surgery was associated with similar overall survival and disease-specific survival outcomes compared with open surgery in patients with early-stage kidney cancer.
Tivozanib May Be Superior Treatment for Patients With RCC, Study Finds
May 29, 2020
When compared with sorafenib, tivozanib showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma.
RCC 2018: Systemic therapy landscape sees rapid change
January 18, 2019
Dr. Kutikov discuss several noteworthy studies about kidney cancer from 2018.
RCC 2018: Top advances in treatment of localized, advanced disease
January 18, 2019
"2018 was an exciting and productive year for kidney cancer research," write Amr A. Elbakry, MBBCh, MSc, and Ketan K. Badani, MD.
ISGF3 activation may inhibit tumor growth in clear cell RCC patients
December 03, 2018
Activating interferon stimulated gene factor 3 could be a new direction for treating clear cell renal cell carcinoma, according to a recent study.
Advanced RCC combo Tx significantly improves PFS
December 03, 2018
“The efficacy benefit and the favorable safety profile support aveluamb plus axitinib as a new first-line standard of care for advanced RCC,” says researcher Robert J. Motzer, MD.